Menu

Psychiatry Couch

About Psychiatry Couch

http://PsychiatryCouch.com

Posts by Psychiatry Couch:

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

, ,

Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif. and LONDON, Nov. 11, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 […]

Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C

Once-Daily Combination Achieves High SVR12 Rates Across Multiple HCV Genotypes BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi® by the U.S. Food and Drug […]

Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

, , ,

High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease BOSTON–(BUSINESS WIRE)–Nov. 11, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating investigational uses of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic hepatitis C virus (HCV) infection in patients with […]

Rite Aid and National Foundation for Infectious Diseases Survey Indicates Most U.S. Women Believe They Are Not Up To Date on Vaccinations

,

Rite Aid Launches Online and In-Store Consumer Education Effort To Help Raise Immunization Awareness Camp Hill, Pa. (Nov. 10, 2014) – A national survey from Rite Aid (NYSE: RAD) and National Foundation for Infectious Diseases (NFID) reveals that the majority of adult women living in the United States do not believe they are up to […]

SpendWell Health announces its participation in the upcoming 2014 IHC FORUM West conference

,

ATLANTA, NOVEMBER 10, 2014 -– SpendWell Health™ – part of the Cambia Health Solutions group – will be highlighting their innovative online marketplace at the 2014 IHC FORUM West conference taking place November 10-12, 2014 at the Red Rock Resort Spa & Casino in Las Vegas. SpendWell’s online marketplace helps employees with high-deductible health plans […]

FDA Accepts Amgen’s Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

, ,

THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a […]

Interim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting®

, ,

Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON, November 9, 2014–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential […]

Rite Aid and HealthSpot Announce Plans to Pilot HealthSpot Stations

,

CAMP HILL, Pa. (November 7, 2014) – Rite Aid announced today it has entered into an agreement with HealthSpot®, a pioneer in patient and provider driven healthcare technology, to provide convenient healthcare services via private, walk-in HealthSpot stations inside select Rite Aid locations. Rite Aid will pilot the HealthSpot stations in the greater Akron/Canton, Cleveland […]

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

, , ,

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

,

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company’s Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company’s oncology and […]

«‹ 15 16 17 18›»